Journal
JOURNAL OF MOLECULAR DIAGNOSTICS
Volume 10, Issue 2, Pages 111-122Publisher
ELSEVIER SCIENCE INC
DOI: 10.2353/jmoldx.2008.070115
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA113669-05, R01 CA113669-02, R01 CA113669-03, R01 CA113669, R01 CA113669-01, R01 CA113669-04, R01CA113669] Funding Source: Medline
- NIDDK NIH HHS [R21 DK072532, R21DK072532] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA113669] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK072532] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (ie, pancreatic cancer) is among the most devastating of human malignancies. it is commonly diagnosed at advanced, already metastatic, and, hence, incurable stages. Despite extensive research efforts in recent decades, pancreatic cancer remains resistant to almost all clinically available therapy regimens. Recent advances in our understanding of the underlying pathophysiology and molecular biology have opened up avenues for the development of novel diagnostic and therapeutic strategies, some of which have shown highly promising preclinical results and are currently being translated into clinical application. Here in we present a review of recent literature on the molecular genetics of pancreatic cancer and emphasize clinical implications for the development of novel diagnostic and therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available